Loading cancer entity…
Loading cancer entity…
Clinical trials
79 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03076554 | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | active not recruiting | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03968315 | An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma | active not recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 |
| clinicaltrials |
| NCT05150210 | SP Thoracic IDE Study | active not recruiting | N/A | 32 | Intuitive SurgicalINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06248515 | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | recruiting | Phase 2 | 18 | Georgetown UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01950572 | Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma | recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04417660 | Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05104736 | PT-112 in Subjects With Thymoma and Thymic Carcinoma | recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01025089 | Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma | active not recruiting | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03295227 | Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer | recruiting | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07693855 | Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors(THOR) | not yet recruiting | N/A | 69 | National Taiwan University HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03134118 | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)(NIVOTHYM) | active not recruiting | Phase 2 | 55 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | May 15, 2026 | clinicaltrials |
| NCT07571525 | Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis(TAILOR-MG) | not yet recruiting | — | 40 | IRCCS San RaffaeleOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT02633553 | Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection | recruiting | N/A | 238 | Fudan UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07328074 | Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis | not yet recruiting | — | 70 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT01385722 | Molecular Analysis of Thoracic Malignancies | enrolling by invitation | — | 1,000 | Stanford UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06838910 | Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma | recruiting | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06186726 | Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors | recruiting | Phase 2 | 48 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06730308 | Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma | recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06692062 | Hypofractionated Radiotherapy for Thymic Epithelial Tumors | recruiting | N/A | 100 | Rongrong ZhouOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05682742 | Clinical Investigation of the da Vinci Surgical System | active not recruiting | N/A | 53 | Intuitive SurgicalINDUSTRY | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06301945 | Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors(INTHYM) | recruiting | — | 1,020 | Erasmus Medical CenterOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06029621 | Robot-assisted vs VATS for Thymoma | recruiting | N/A | 304 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05832827 | First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)(Artemis) | recruiting | Phase 2 | 35 | National Cancer Center, JapanOTHER_GOV | 1 | Oct 23, 2023 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials